Key Points
- CeriBell CTO Raymond Woo sold 4,887 shares at an average price of $24.38, generating proceeds of approximately $119,145 and reducing his ownership by 2.35% to 203,118 shares.
- CeriBell reported quarterly revenue of $28.10 million, exceeding estimates, but its adjusted loss of $0.51 per share was wider than expected. Analysts project a full-year loss of $1.96 per share.
- Despite the insider selling and ongoing losses, analysts maintain a “Moderate Buy” consensus with an average price target of $27, while institutional investors including BlackRock and Bank of America have increased or initiated positions.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 4,887 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $24.38, for a total transaction of $119,145.06. Following the completion of the transaction, the chief technology officer directly owned 203,118 shares in the company, valued at approximately $4,952,016.84. The trade was a 2.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Raymond Woo also recently made the following trade(s):
- On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The shares were sold at an average price of $24.33, for a total transaction of $118,900.71.
- On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $47,535.58.
CeriBell Stock Performance
CBLL stock opened at $23.69 on Friday. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.63. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The company has a market cap of $909.22 million, a P/E ratio of -13.46 and a beta of 0.94. The business's fifty day moving average is $22.78 and its 200-day moving average is $20.24.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Equities research analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.
Wall Street Analyst Weigh In
A number of analysts have recently commented on CBLL shares. Weiss Ratings raised CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 14th. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Raymond James Financial restated a "strong-buy" rating and set a $29.00 price objective on shares of CeriBell in a report on Thursday, September 3rd. TD Cowen increased their target price on shares of CeriBell from $29.00 to $33.00 and gave the stock a "buy" rating in a report on Friday. Finally, BTIG Research reissued a "buy" rating and set a $30.00 price target on shares of CeriBell in a research report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $27.00.
Get Our Latest Report on CeriBell
Institutional Investors Weigh In On CeriBell
Several large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of CeriBell during the second quarter worth about $37,657,000. KCM Capital Inc grew its position in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of CeriBell in the 2nd quarter valued at approximately $17,437,000. TimesSquare Capital Management LLC bought a new stake in CeriBell during the 2nd quarter worth approximately $15,182,000. Finally, Bank of America Corp DE raised its holdings in CeriBell by 15.3% during the 1st quarter. Bank of America Corp DE now owns 319,837 shares of the company's stock worth $5,863,000 after buying an additional 42,340 shares during the period.
CeriBell Company Profile
(
Get Free Report)
CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.
The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
